国药现代：子公司盐酸氢吗啡酮注射液获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its hydrochloride hydromorphone injection, indicating its capability to produce and sell this product in the domestic market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has obtained the drug registration certificate for hydrochloride hydromorphone injection [1] - The hydrochloride hydromorphone injection (1ml:2mg) is intended for patients requiring opioid analgesia [1] - The approval signifies that the product has passed the consistency evaluation, allowing the company to enter the domestic market for this medication [1] Group 2: Market Considerations - The sales of the drug may be influenced by industry policies, tender procurement, and market conditions, which introduces uncertainty [1]